Cargando…
Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma
BACKGROUND: Glypican-3 (GPC-3) is an oncofetal protein that is highly expressed in various solid tumors, but rarely expressed in healthy adult tissues and represents a rational target of particular relevance in hepatocellular carcinoma (HCC). Autologous chimeric antigen receptor (CAR) αβ T cell ther...
Autores principales: | Makkouk, Amani, Yang, Xue (Cher), Barca, Taylor, Lucas, Anthony, Turkoz, Mustafa, Wong, Jonathan T S, Nishimoto, Kevin P, Brodey, Mary M, Tabrizizad, Maryam, Gundurao, Smitha R Y, Bai, Lu, Bhat, Arun, An, Zili, Abbot, Stewart, Satpayev, Daulet, Aftab, Blake T, Herrman, Marissa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679077/ https://www.ncbi.nlm.nih.gov/pubmed/34916256 http://dx.doi.org/10.1136/jitc-2021-003441 |
Ejemplares similares
-
Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma
por: Sun, Ming, et al.
Publicado: (2023) -
Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors
por: Foster, Jessica B, et al.
Publicado: (2022) -
Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma
por: Sun, Luan, et al.
Publicado: (2021) -
'Off-the-shelf’ allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies
por: Sinha, Debottam, et al.
Publicado: (2021) -
Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity
por: Zanetti, Samanta Romina, et al.
Publicado: (2020)